Table 1 Clinical characteristics at baseline and secondary clinical outcomes of the two groups
Placebo (n= 13) | Vitamin D (n= 12) | P value | |
|---|---|---|---|
Baseline characteristics | |||
Male - n (%) | 10 (77) | 9 (75) | 0.91 |
Age (years) | 64.1 ± 16.4 | 61.1 ± 16.7 | 0.65 |
Body mass Index (kg/m2) | 29.3 ± 8.5 | 28.7 ± 9.7 | 0.87 |
SAPS II (ICU admission) | 38.3 ± 22.3 | 33.2 ± 12.2 | 0.47 |
TISS (study start) | 38.0 ± 7.2 | 30.2 ± 7.1 | 0.08 |
Renal replacement therapy - n (%) | 3 (23) | 1 (8) | 0.31 |
Diagnostic category | infectious (4) | infectious (6) | |
cardiovascular (4) | cardiovascular (3) | ||
neurologic (4) | neurologic (1) | - | |
gastrointestinal (1) | gastrointestinal (0) | ||
other (0) | other (2) | ||
Mechanical ventilation - n (%) | 11 (85) | 10 (83) | 0.93 |
Vasopressor therapy - n (%) | 12 (92) | 8 (67) | 0.10 |
Outcome variables | |||
Mechanical ventilation - duration (hours) | 163 (91-541) | 229 (82-366) | 0.88 |
Vasopressor therapy - duration (hours) | 146 (48-351) | 65 (42-299) | 0.56 |
Hospital stay, days (from study start) | 15 (8-38) | 16 (8-32) | 0.97 |
ICU stay, days (from study start) | 6 (3-23) | 10 (5-21) | 0.54 |
Hospital mortality - n (%) | 6 (46) | 6 (50) | 0.84 |